Linagliptin/metformin - Dong Wha Pharmaceutical
Alternative Names: DW-6013Latest Information Update: 15 Oct 2025
At a glance
- Originator Dong Wha Pharmaceutical
- Class Alkynes; Antihyperglycaemics; Biguanides; Insulin sensitisers; Piperidines; Purines; Quinazolines; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Dipeptidyl peptidase 4 inhibitors; Gluconeogenesis inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Diabetes mellitus
Most Recent Events
- 15 Oct 2025 Phase-I development is ongoing in Diabetes mellitus (In volunteers) in South Korea (PO) (Dong Wha Pharmaceutical pipeline; October 2025)
- 14 Aug 2023 Chemical structure information added
- 03 Feb 2023 Dong Wha Pharmaceutical completes a phase I trial in Diabetes mellitus (In volunteers) in South Korea (PO) (NCT05874180)